Zai Lab Limited (FRA:1ZL)

Market Cap	1.55B -40.3%
Revenue (ttm)	376.40M +24.1%
Net Income	-176.27M
EPS	-1.64
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	33
Open	15.30
Previous Close	15.90
Day's Range	15.30 - 15.30
52-Week Range	14.20 - 38.20
Beta	n/a
RSI	34.77
Earnings Date	Feb 27, 2026

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 1,869
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1ZL

Financial Performance

In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.

Financial numbers in USD